 |
12 Products |  |
51 Diseases | | 12 Products |
|
10 Trials |  |
1329 News |  |
| «12...567891011121314151617» |
- || remetinostat (SHP-141) / Medivir
Trial primary completion date, Epigenetic controller: Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma (clinicaltrials.gov) - Oct 20, 2016
P2, N=60, Active, not recruiting, Sponsor: TetraLogic Pharmaceuticals
Trial primary completion date: May 2016 --> Oct 2016
- | remetinostat (SHP-141) / Medivir
Trial initiation date, Trial primary completion date, Epigenetic controller: Safety and Efficacy Study of SHAPE Gel in Alopecia Areata (clinicaltrials.gov) - Oct 20, 2016
P2, N=40, Not yet recruiting, Sponsor: TetraLogic Pharmaceuticals
Trial primary completion date: May 2016 --> Oct 2016 Initiation date: Feb 2016 --> Feb 2017 | Trial primary completion date: Nov 2016 --> Aug 2017
- ||| birinapant (IGM-9427) / IGM Biosciences
Trial initiation date, Trial primary completion date, Combination therapy: KEYNOTE 163: Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors (clinicaltrials.gov) - Oct 20, 2016
P1/2, N=104, Not yet recruiting, Sponsor: TetraLogic Pharmaceuticals
Initiation date: Feb 2016 --> Feb 2017 | Trial primary completion date: Nov 2016 --> Aug 2017 Initiation date: Dec 2015 --> Feb 2017 | Trial primary completion date: Mar 2019 --> Jan 2021
- | odalasvir (ACH-3102) / J&J, AstraZeneca, adafosbuvir (AL-335) / J&J, Medivir
Trial completion: Study to Investigate the Pharmacokinetics, Safety and Tolerability of Odalasvir and AL-335 in Healthy Japanese Participants (clinicaltrials.gov) - Oct 18, 2016
P1, N=40, Completed, Sponsor: Janssen Research & Development, LLC
Initiation date: Dec 2015 --> Feb 2017 | Trial primary completion date: Mar 2019 --> Jan 2021 Recruiting --> Completed
- Trial primary completion date: GEHEP: Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions (clinicaltrials.gov) - Oct 17, 2016
P=N/A, N=1000, Recruiting, Sponsor: Valme University Hospital
Recruiting --> Completed Trial primary completion date: Nov 2017 --> Nov 2020
- Trial primary completion date: Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients (clinicaltrials.gov) - Oct 17, 2016
P=N/A, N=1000, Recruiting, Sponsor: Valme University Hospital
Trial primary completion date: Nov 2017 --> Nov 2020 Trial primary completion date: Dec 2017 --> Dec 2020
- | Olysio (simeprevir) / J&J, Medivir
Phase classification, Combination therapy: An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection (clinicaltrials.gov) - Oct 14, 2016
P2a, N=63, Completed, Sponsor: Janssen-Cilag International NV
Trial primary completion date: Dec 2017 --> Dec 2020 Phase classification: P2 --> P2a
- |||| Olysio (simeprevir) / J&J, Medivir
Trial completion, Enrollment change, Trial primary completion date: Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1 (clinicaltrials.gov) - Oct 13, 2016
P4, N=60, Completed, Sponsor: Stanford University
Phase classification: P2 --> P2a Not yet recruiting --> Completed | N=30 --> 60 | Trial primary completion date: Oct 2017 --> Aug 2016
- Olysio (simeprevir) / J&J, Medivir
Trial primary completion date: Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis (clinicaltrials.gov) - Oct 11, 2016
P3, N=9, Active, not recruiting, Sponsor: University of Colorado, Denver
Not yet recruiting --> Completed | N=30 --> 60 | Trial primary completion date: Oct 2017 --> Aug 2016 Trial primary completion date: Aug 2016 --> Dec 2017
- adafosbuvir (AL-335) / J&J, Medivir
Enrollment open: A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335 (clinicaltrials.gov) - Oct 8, 2016
P1, N=32, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Aug 2016 --> Dec 2017 Not yet recruiting --> Recruiting
- Enrollment open, Combination therapy: To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants (clinicaltrials.gov) - Sep 29, 2016
P1, N=24, Recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Phase classification, Enrollment change, Trial initiation date, Trial primary completion date: Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection (clinicaltrials.gov) - Sep 9, 2016
P2b, N=300, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Phase classification: P2 --> P2b | N=400 --> 300 | Initiation date: Jun 2016 --> Nov 2016 | Trial primary completion date: Apr 2017 --> Jul 2017
- | adafosbuvir (AL-335) / J&J, Medivir
New P1 trial: A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335 (clinicaltrials.gov) - Sep 9, 2016
P1, N=32, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- | New P1 trial, Combination therapy: To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants (clinicaltrials.gov) - Aug 30, 2016
P1, N=24, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- Pegasys (pegylated interferon α -2a) / Roche, Sunvepra (asunaprevir) / BMS, Olysio (simeprevir) / J&J, Medivir
Trial primary completion date: SWITCH-1: Switching Regimen in Treating Cirrhotic HCV GT1b Subjects (clinicaltrials.gov) - Aug 22, 2016
P2, N=160, Recruiting, Sponsor: Humanity & Healthy GI and Liver Centre
Phase classification: P2 --> P2b | N=400 --> 300 | Initiation date: Jun 2016 --> Nov 2016 | Trial primary completion date: Apr 2017 --> Jul 2017 Trial primary completion date: Sep 2016 --> Dec 2016
- Adasuve (staccato loxapine) / AOP Orphan Pharma, Teva, Ferrer International, Galen, Medivir
Trial completion, Enrollment change, Trial primary completion date: OAMED: Outcomes of Antipsychotic Medication Used in the Emergency Department (clinicaltrials.gov) - Jul 28, 2016
P=N/A, N=93, Completed, Sponsor: Advocate Health Care
Trial primary completion date: Sep 2016 --> Dec 2016 Enrolling by invitation --> Completed | N=150 --> 93 | Trial primary completion date: Oct 2015 --> Mar 2016
- | Olysio (simeprevir) / J&J, Medivir
Trial completion, Enrollment change: SMV + SOF With/Without RBV for IFN-II Patients With CHC (clinicaltrials.gov) - Jul 8, 2016
P4, N=24, Completed, Sponsor: SC Liver Research Consortium, LLC
Enrolling by invitation --> Completed | N=150 --> 93 | Trial primary completion date: Oct 2015 --> Mar 2016 Active, not recruiting --> Completed | N=40 --> 24
- | New P1 trial: Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese Participants (clinicaltrials.gov) - Jul 6, 2016
P1, N=16, Recruiting, Sponsor: Janssen Research & Development, LLC
- | odalasvir (ACH-3102) / J&J, AstraZeneca, adafosbuvir (AL-335) / J&J, Medivir
New P1 trial: Study to Investigate the Pharmacokinetics, Safety and Tolerability of Odalasvir and AL-335 in Healthy Japanese Participants (clinicaltrials.gov) - Jul 5, 2016
P1, N=40, Recruiting, Sponsor: Janssen Research & Development, LLC
- |||| Olysio (simeprevir) / J&J, Medivir
Trial completion, Enrollment change: ACCORDION-1: Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection (clinicaltrials.gov) - Jun 28, 2016
P2, N=68, Completed, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed | N=40 --> 24 Recruiting --> Completed | N=90 --> 68
- | Olysio (simeprevir) / J&J, Medivir
Trial completion: A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection (clinicaltrials.gov) - May 31, 2016
P2, N=41, Completed, Sponsor: Janssen Sciences Ireland UC
Recruiting --> Completed | N=90 --> 68 Recruiting --> Completed
- Olysio (simeprevir) / J&J, Medivir
Enrollment closed, Enrollment change: Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis (clinicaltrials.gov) - May 19, 2016
P3, N=9, Active, not recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Completed Recruiting --> Active, not recruiting | N=25 --> 9
- ||| Enrollment change: A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir (clinicaltrials.gov) - May 13, 2016
P2, N=140, Recruiting, Sponsor: Alios Biopharma Inc.
Recruiting --> Active, not recruiting | N=25 --> 9 N=60 --> 140
- || Olysio (simeprevir) / J&J, Medivir, Daklinza (daclatasvir) / BMS
New P3 trial: FRI-STC: Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC (clinicaltrials.gov) - May 13, 2016
P3, N=150, Recruiting, Sponsor: National Hepatology & Tropical Medicine Research Institute
- ||||| New P2 trial: Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection (clinicaltrials.gov) - May 6, 2016
P2, N=400, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- |||| Olysio (simeprevir) / J&J, Medivir
Trial completion: COMMIT: A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants (clinicaltrials.gov) - May 5, 2016
P2, N=106, Completed, Sponsor: Janssen-Cilag International NV
N=60 --> 140 Active, not recruiting --> Completed
- New trial: Impact of Antiviral Therapy on Gastroesophageal Varices. (clinicaltrials.gov) - May 2, 2016
P=N/A, N=374, Active, not recruiting, Sponsor: Parc de Salut Mar
- | birinapant (IGM-9427) / IGM Biosciences
New P2 trial, Combination therapy: Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - May 2, 2016
P2, N=34, Not yet recruiting, Sponsor: Jonsson Comprehensive Cancer Center
- | birinapant (IGM-9427) / IGM Biosciences
Trial completion, Enrollment change, Combination therapy: Birinapant With 5-azacitidine in MDS Subjects Who Are Na (clinicaltrials.gov) - Apr 21, 2016
P1/2, N=21, Completed, Sponsor: TetraLogic Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=45 --> 21
- ||||| MIV 710 / Medivir, MIV-711 / Medivir
New P2a trial: A Study to Evaluate the Efficacy, Safety and Tolerability of MIV-711 in Osteoarthritis Patients (clinicaltrials.gov) - Mar 10, 2016
P2a, N=240, Recruiting, Sponsor: Medivir
- | Olysio (simeprevir) / J&J, Medivir
New P4 trial: Sofosbuvir/Simeprevir Plus a Flat Dose of Ribavirin in Genotype 1 Elderly HCV Cirrhotic Patients (clinicaltrials.gov) - Mar 9, 2016
P4, N=270, Completed, Sponsor: Azienda Ospedaliera San Camillo Forlanini
- || birinapant (IGM-9427) / IGM Biosciences
Trial primary completion date, Combination therapy, Metastases: Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Mar 5, 2016
P1b/2a, N=176, Completed, Sponsor: TetraLogic Pharmaceuticals
Active, not recruiting --> Completed | N=45 --> 21 Trial primary completion date: Mar 2014 --> Oct 2013
- Olysio (simeprevir) / J&J, Medivir
Trial completion, Trial primary completion date: The SIM-SOF Trial for Hepatitis C (clinicaltrials.gov) - Mar 5, 2016
P4, N=82, Completed, Sponsor: Center For Hepatitis C, Atlanta, GA
Trial primary completion date: Mar 2014 --> Oct 2013 Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Dec 2014
- Sunvepra (asunaprevir) / BMS, Olysio (simeprevir) / J&J, Medivir, Daklinza (daclatasvir) / BMS
Trial completion: Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects (clinicaltrials.gov) - Mar 1, 2016
P2, N=18, Completed, Sponsor: Humanity & Healthy GI and Liver Centre
Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Dec 2014 Recruiting --> Completed
- | Olysio (simeprevir) / J&J, Medivir
Trial completion, Combination therapy: Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection (clinicaltrials.gov) - Feb 24, 2016
P2, N=30, Completed, Sponsor: Peter J. Ruane, M.D.
Recruiting --> Completed Recruiting --> Completed
- |||| Olysio (simeprevir) / J&J, Medivir
Trial completion, HEOR: A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir (clinicaltrials.gov) - Feb 22, 2016
P4, N=315, Completed, Sponsor: Janssen Scientific Affairs, LLC
Recruiting --> Completed Active, not recruiting --> Completed
- Olysio (simeprevir) / J&J, Medivir, Tivicay (dolutegravir) / ViiV Healthcare
Enrollment open, Trial initiation date, Trial primary completion date: Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers (clinicaltrials.gov) - Feb 4, 2016
P=N/A, N=25, Recruiting, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Oct 2015 --> Feb 2016 | Trial primary completion date: Dec 2015 --> Oct 2016
- ||| remetinostat (SHP-141) / Medivir
Enrollment closed, Epigenetic controller: Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma (clinicaltrials.gov) - Feb 4, 2016
P2, N=60, Active, not recruiting, Sponsor: TetraLogic Pharmaceuticals
Not yet recruiting --> Recruiting | Initiation date: Oct 2015 --> Feb 2016 | Trial primary completion date: Dec 2015 --> Oct 2016 Recruiting --> Active, not recruiting
- |||| Enrollment open, Trial primary completion date: A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir (clinicaltrials.gov) - Feb 1, 2016
P2, N=60, Recruiting, Sponsor: Alios Biopharma Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2016 --> Jun 2016
- || adafosbuvir (AL-335) / J&J, Medivir
Trial primary completion date: First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 (clinicaltrials.gov) - Jan 29, 2016
P1, N=70, Recruiting, Sponsor: Alios Biopharma Inc.
Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2016 --> Jun 2016 Trial primary completion date: Jun 2015 --> Apr 2016
- JNJ-54257099 / Medivir, J&J
Enrollment change, Trial termination: First in Human Study of AL-704; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C (clinicaltrials.gov) - Jan 29, 2016
P1, N=40, Terminated, Sponsor: Alios Biopharma Inc.
Trial primary completion date: Jun 2015 --> Apr 2016 N=96 --> 40 | Recruiting --> Terminated
- | Trial completion: A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers (clinicaltrials.gov) - Jan 29, 2016
P1, N=32, Completed, Sponsor: Alios Biopharma Inc.
N=96 --> 40 | Recruiting --> Terminated Recruiting --> Completed
- | Olysio (simeprevir) / J&J, Medivir
Enrollment closed, Trial primary completion date: SMV + SOF With/Without RBV for IFN-II Patients With CHC (clinicaltrials.gov) - Jan 26, 2016
P4, N=40, Active, not recruiting, Sponsor: SC Liver Research Consortium, LLC
Recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> Jun 2016
- | Olysio (simeprevir) / J&J, Medivir
Trial completion: An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant (clinicaltrials.gov) - Jan 25, 2016
P2, N=46, Completed, Sponsor: Janssen Scientific Affairs, LLC
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> Jun 2016 Active, not recruiting --> Completed
- || Olysio (simeprevir) / J&J, Medivir
Trial completion, Combination therapy: Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection (clinicaltrials.gov) - Jan 21, 2016
P3, N=40, Completed, Sponsor: Janssen R&D Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Olysio (simeprevir) / J&J, Medivir
Trial completion: 3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection (clinicaltrials.gov) - Jan 20, 2016
P2b, N=249, Completed, Sponsor: Janssen R&D Ireland
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | birinapant (IGM-9427) / IGM Biosciences, conatumumab (AMG 655) / Amgen
Trial completion, Enrollment change, Combination therapy: Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer (clinicaltrials.gov) - Jan 15, 2016
P1, N=27, Completed, Sponsor: TetraLogic Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=40 --> 27
- | birinapant (IGM-9427) / IGM Biosciences
Enrollment change, Trial termination, Trial primary completion date: Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL (clinicaltrials.gov) - Jan 11, 2016
P2, N=118, Terminated, Sponsor: TetraLogic Pharmaceuticals
Active, not recruiting --> Completed | N=40 --> 27 N=158 --> 118 | Recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Jan 2016; Study terminated due to lack of efficacy
- |||| Olysio (simeprevir) / J&J, Medivir
Trial completion, Combination therapy: An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection (clinicaltrials.gov) - Dec 29, 2015
P2, N=63, Completed, Sponsor: Janssen-Cilag International NV
N=158 --> 118 | Recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Jan 2016; Study terminated due to lack of efficacy Active, not recruiting --> Completed
- | remetinostat (SHP-141) / Medivir
New P2 trial, Epigenetic controller: Safety and Efficacy Study of SHAPE Gel in Alopecia Areata (clinicaltrials.gov) - Dec 21, 2015
P2, N=40, Not yet recruiting, Sponsor: TetraLogic Pharmaceuticals